The Prospect of Anavex Prophylaxis
The CTAD symptoms response plots clearly showed that A2-73 did one of two things: either stabilized, maintained symptomatic progression, holding things at a stable, at-the-start level; or, even more significantly, it actually reversed mental and functional declines. Toward the end of the trial, participants scored higher than at the start.
Nothing on the shelves of pharmacies, nor anything reported from the labs and clinical trials of any other drug company has ever shown such favorable plots of clinical data.
Right now, all of us with an interest in both Anavex perspectives: relief for victims, and financial rewards for AVXL investors; are understandably focusing on what A2-73 has been shown to do for Alzheimer’s patients: hold them steady, or even improve their conditions. Alone, those results should prompt eventual FDA approval.
But as good as we can imagine those outcomes to be, I’m certain they will be eclipsed when, eventually, it is determined that the best and most effective use of A2-73 and A3-71 will be for prophylaxis, used to PREVENT the onset of Alzheimer’s, Parkinson’s, ALS, and other neurodegenerative central nervous system diseases.
If Anavex drugs can stop disease progression, or even reverse it to any degree after symptoms appear, there is every good reason to believe administration before symptoms appear could keep them chronically and sub-clinically suppressed at length. Take the stuff to keep any of the CNS diseases from ever starting. The cost savings and health benefits will be, without exaggeration, the best of any medical development since antibiotics changed things in the late 40s and early 50s.
